Please note that this meeting will take place as an in-person event in Austin and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the Registration page for details.

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise.  Program in progress.

[R] – Remote Presentation
*– Short talk selected from proffered abstracts

thursday, november 17, 2022

Preneoplasia: Definitions, PreCancer Atlas and Resources
NCI Funding for Precision Prevention Research
Welcome and Introduction
Opening Keynote Address
A Vision for The Future of Cancer Prevention: Three Perspectives

friday, november 18, 2022

Breakfast Session I: Multicancer Early Detection Tests: New Data and Perspectives
Plenary Session 1: What Will Cancer Prevention and Early Detection Look like in 2041? 
Plenary Session 2:  Defining a Molecular Basis for Cancer Prevention and Early Detection
Panel Discussion: How Can We Merge Novel Technologies with Knowledge of Cancer Mechanisms to Improve Early Detection of Cancer? 
Plenary Session 3: Preneoplastic Conditions as a Model for Early Detection 
Plenary Session 4:  Innovative Approaches for Implementation – Community, Regulatory, and Operational 
Spotlight on Proffered Papers I 

Saturday, november 19, 2022

Breakfast Session II: Multicancer Early Detection Tests: New Data and Perspectives
Keynote Address
Plenary Session 5: Prevention and Interception 
Spotlight on Proffered Papers II 
Plenary Session 6:  Technological Advances and Their Application in Early Detection  

thursday, november 17, 2022

preneoplasia: definitions, precancer atlas and resources
not eligible for cme credit
3-5 p.m.

Introduction to the NCI’s PreCancer as Part of the Human Tumor Atlas Network
Sudhir Srivastava, National Cancer Institute, Bethesda, Maryland
Sharmistha Ghosh-Janjigian, National Cancer Institute, Bethesda, Maryland

Panel Discussion I: Definition of PreCancer: Viewpoints
Biology of Incipient and Precancer
Lead Discussant: Eduardo Vilar-Sanchez, The University of Texas MD Anderson Cancer Center, Houston, Texas
Panelist: Veronica M. Rotemberg, Memorial Sloan Kettering Cancer Center, New York, New York

Anatomical and Clinical Pathological Definition of Precancer: Familial, Hereditary and Sporadic
Lead Discussant: Ernest T. Hawk, The University of Texas MD Anderson Cancer Center, Houston, Texas
Panelist: Andrew T. Chan, Massachusetts General Hospital, Boston, Massachusetts

Molecular, Cellular, and Immuno-pathology of Precancer
Lead Discussant: Mary L. Disis, University of Washington, Seattle, Washington
Panelists:
Adewole S. Adamson, The University of Texas at Austin Dell Medical School, Austin, Texas
Joshua LaBaer, The Biodesign Institute at Arizona State University, Tempe, Arizona
Scott M. Lippman, Moores Cancer Center at UC San Diego Health, La Jolla, California [R]

Panel Discussion II: New Directions to Strengthen the Current Atlas Activities
Moderator: Sudhir Srivastava, National Cancer Institute, Bethesda, Maryland
Panelists:
Scott M. Lippman, Moores Cancer Center at UC San Diego Health, La Jolla, California [R]
Ernest T. Hawk, The University of Texas MD Anderson Cancer Center, Houston, Texas
Joshua LaBaer, The Biodesign Institute at Arizona State University, Tempe, Arizona
Timothy R. Rebbeck, Dana-Farber Cancer Institute, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
David Crosby, Cancer Research UK, London, England, United Kingdom
Philip E. Castle, National Cancer Institute, Bethesda, Maryland

nci funding for precision prevention research
not eligible for cme credit
moderator: goli samimi, national cancer institute, bethesda, maryland
3-4:30 p.m.

Welcome
Philip E. Castle, National Cancer Institute, Bethesda, Maryland

Investigator-initiated Grant Opportunities for Precision Prevention
Brandy Heckman-Stoddard, National Cancer Institute, Bethesda, Maryland

Training Grant Opportunities at NCI
Mark Damico, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

DCP/NCI Research Resources
Asad Umar, National Cancer Institute, Bethesda, Maryland

Program Director Roundtable
Moderator: Goli Samimi, National Cancer Institute, Bethesda, Maryland
Discussants:
Brandy Heckman-Stoddard, National Cancer Institute, Bethesda, Maryland
Mark Damico, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Asad Umar, National Cancer Institute, Bethesda, Maryland
Edward Sauter, National Cancer Institute, Bethesda, Maryland
Altaf Mohammed, National Cancer Institute, Bethesda, Maryland

Welcome and introduction 
6-6:10 p.m.

Welcome from conference chair and cochairs

opening keynote address
6:10-7 P.m.

Introduction of keynote speaker
Timothy R. Rebbeck, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, Massachusetts

Innovation and equity in cancer prevention and screening
Douglas R. Lowy, National Cancer Institute, Bethesda, Maryland

a vision for the future of cancer prevention: three perspectives
moderator: timothy R. rebbeck, dana-farber cancer institute, harvard t.h. chan school of public health, boston, massachusetts 
7-8 p.m. 

Adriana Albini, University Milano-Bicocca, Milan, Italy [R]

Philip E. Castle, National Cancer Institute, Bethesda, Maryland

David Crosby, Cancer Research UK, London, England, United Kingdom

Panel Discussion
Panelists:
Douglas R. Lowy, National Cancer Institute, Bethesda, Maryland
Adriana Albini, University Milano-Bicocca, Milan, Italy [R]
Philip E. Castle, National Cancer Institute, Bethesda, Maryland
David Crosby, Cancer Research UK, London, England, United Kingdom

Opening Reception  
8-9:30 p.m.

friday, november 18, 2022

Continental Breakfast 
7-8 a.m. 

breakfast session I: multicancer early detection tests: new data and perspectives
Not eligible for cme credit
session chair: Christina Clarke Dur, Grail Inc. Menlo Park, CAlifornia
7-8 a.m.

Assessing implementation of a multi-cancer early detection blood test for population screening in a clinical practice setting: Prospective PATHFINDER cohort study
Eric A. Klein, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio

Improved sensitivity of a multi-analyte early detection test based on mutation, methylation, aneuploidy, and protein biomarkers
Frank Diehl, Exact Sciences Corp., Cambridge, Massachusetts

break
8-8:30 A.m.

Plenary Session 1: What Will Cancer Prevention and Early Detection Look like in 2041? 
SESSION CHAIR: TIMOTHY R. REBBECK, DANA-FARBER CANCER INSTITUTE, HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH, BOSTON, MASSACHUSETTS 
8:30-10 a.m.   

Optimizing the public’s health through prevention and early detection (precision and otherwise) 
Timothy R. Rebbeck, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, Massachusetts

Aspirin and cancer: What’s next?  
Andrew T. Chan, Massachusetts General Hospital, Boston, Massachusetts

Molecular imaging and multicancer detection for precision medicine
Katherine W. Ferrara, Stanford University, Stanford, California

Break 
10-10:30 a.m.  

plenary session 2: defining a molecular basis for cancer prevention and early detection
session chair: luis a. diaz, jr., memorial sloan kettering cancer center, new york, new york
10:30 a.m.-12 p.m.

Title to be announced
Nickolas Papadopoulos, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Title to be announced
Daniel D. De Carvalho, University Health Network Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Early detection of cancer using cell-free DNA fragmentomes
Victor E. Velculescu, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
   

Lunch 
12-1 p.m. 

Panel Discussion: How Can We Merge Novel Technologies with Knowledge of Cancer Mechanisms to Improve Early Detection of Cancer? 
MODERATOR: Katherine W. Ferrara, Stanford University, Stanford, California
12:15-1:15 p.m. 

Panelists:  

Joshua LaBaer, The Biodesign Institute at Arizona State University, Tempe, Arizona 

Sudhir Srivastava, National Cancer Institute, Bethesda, Maryland 

Victor E. Velculescu, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Break 
1:15-1:45 p.m. 

Plenary Session 3: Preneoplastic Conditions as a Model for Early Detection 
SESSION CHAIR: ernest t. hawk, the university of texas md anderson cancer center, houston, texas
1:45-3:15 p.m. 

Title to be announced
Kelly L. Bolton, Washington University in St. Louis, St. Louis, Missouri

Early detection and interception of lung cancer via a precancer atlas
Avrum E. Spira, Johnson & Johnson Innovation Center, Boston University, Boston, Massachusetts 

Challenges and opportunities in early detection of melanoma 
Veronica M. Rotemberg, Memorial Sloan Kettering Cancer Center, New York, New York

Break 
3:15-3:45 p.m. 

Plenary Session 4:  Innovative Approaches for Implementation – Community, Regulatory, and Operational  
SESSION CHAIR: ERNEST T. HAWK, THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, HOUSTON, TEXAS
3:45-5:45 p.m. 

Implementation of population-based precision cancer screening programs
Nora Pashayan, University College London, London, England, United Kingdom

Precision Prevention in High-risk populations: The example of Lynch Syndrome
Eduardo Vilar-Sanchez, The University of Texas MD Anderson Cancer Center, Houston, Texas 

Delivering an effective community-driven model to reduce cancer risk at a population level: Results from MD Anderson’s Be Well Communities
Ruth Rechis, The University of Texas MD Anderson Cancer Center, Houston, Texas  

Precision public health approaches to health equity
Derek M. Griffith, Georgetown University, Washington, D.C.

Break 
5:45-6 p.m. 

Spotlight on Proffered Papers I: Immunosuppression 
SESSION CHAIR: PHILIP E. CASTLE, NATIONAL CANCER INSTITUTE, BETHESDA, MARYLAND
6-7 p.m. 

Mechanisms by which Mito-LND inhibits KRAS mutant lung cancer*
Katherine M. Weh, University of Michigan, Ann Arbor, Michigan

A pilot study of a MUC1 vaccine in current and former smokers at high risk for lung cancer*
Arjun Pennathur, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Multiplexed immune phenotyping and miRNA-ISH in bronchial premalignant lesions reveals a mechanism of immune suppression*
Darren J. Chiu, Boston University School of Medicine, Boston, Massachusetts

The role of NOTCH1 in bronchial pre-malignant lesions*
Roxana Pfefferkorn, Boston University School of Medicine, Boston, Massachusetts

Poster Session / Reception 
7-9 p.m. 

Saturday, november 19, 2022 

Continental Breakfast   
7-8 a.m. 

breakfast session II: Multicancer early detection tests: new data and perspectives
not eligible for cme credit
session chair: christina clarke dur, grail inc., menlo park, california
7-8 a.m.

The role of consortia building the paradigm of blood-based early cancer detection
Christina Clarke Dur, Grail Inc., Menlo Park, California

Rethinking risk assessment in the era of multi-cancer early detection
Alpa V. Patel, American Cancer Society, Atlanta, Georgia

break
8-8:30 a.m.

Keynote Address 
8:30-9:30 a.m. 

Introduction of keynote speaker 
Luis A. Diaz, Jr., Memorial Sloan Kettering Cancer Center, New York, New York

Title to be announced 
Minetta C. Liu, Natera, Inc. Austin, Texas

Plenary Session 5: Prevention and Interception 
SESSION CHAIR: LUIS A. DIAZ, JR., MEMORIAL SLOAN KETTERING CANCER CENTER, NEW YORK, NEW YORK 
9:30-11 a.m.  

Vaccine approach for interception of colon cancer
Mary L. Disis, University of Washington, Seattle, Washington

Targeting mTOR for the prevention of triple-negative breast cancer
Powel H. Brown, The University of Texas MD Anderson Cancer Center, Houston, Texas

Opportunity for Interception as a Driver of Benefit in Cancer Early Detection: Implications for Multi-Cancer Early Detection Testing
Ruth D. Etzioni, Fred Hutchinson Cancer Research Center, Seattle, Washington

Boxed Lunch 
11 a.m.-12 p.m. 

Spotlight on Proffered Papers II: General (merit) 
session chair: Timothy Rebbeck, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, Massacusetts
11:15 a.m.-12:15 p.m. 

Features and susceptibility to dietary-induced alkylating damage in colorectal cancer*
Marios Giannakis, Dana-Farber Cancer Institute, Boston, Massachusetts

Screening under-served populations by mobile low dose computerized tomography (LDCT) scans results in stage shift with potential cures: Time for a change in health policy?*
Derek Raghavan, Atrium Health Levine Cancer Institute, Charlotte, North Carolina

A liposomal priming agent increases the sensitivity of liquid biopsies*
Maria Carmen Martin Alonso, Massachusetts Institute of Technology, Cambridge, Massachusetts

Development and testing of a polygenic risk score for breast cancer aggressiveness*
Yiwey Shieh, Weill Cornell Medicine, New York, New York

Break 
12:15-12:30 p.m. 

Plenary Session 6:  Technological Advances and Their Application in Early Detection  
This session is dedicated to the Work and Life of Sanjiv Sam Gambhir, MD, PhD 
SESSION CHAIR:  SANGEETA n. BHATIA, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, CAMBRIDGE, MASSACHUSETTS 
12:30-2 p.m. 

Nanotechnology-enabled approaches for early cancer detection
Sangeeta N. Bhatia, Massachusetts Institute of Technology, Cambridge, Massachusetts

Early cancer detection through the analyses of extracellular vesicles
Hakho Lee, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

Contribution of biomarker based risk profiles to cancer early detection
Samir M. Hanash, The University of Texas MD Anderson Cancer Center, Houston, Texas 

Closing Remarks 
2-2:15 p.m. 

Closing remarks
Luis A. Diaz, Jr., Memorial Sloan Kettering Cancer Center, New York, New York

Times may change slightly as the program develops with the inclusion of short talks from proffered abstracts.